Regina Hodits Email Address

Supervisory Board Member

Wellington Partners invests Venture Capital in Technology and Life Science companies

Senior investment manager with significant international venture capital experience including development of start-ups and spin-offs. Strong scientific background and industry knowledge in the healthcare arena with a qualified overview of other high-growth sectors. Functional expertise in investment identification, due diligence analysis, legal and economic aspects of VC and PE investments, monitoring and development of portfolio companies, exit management and experience in general fund activities including fund management and fund raising. Bio: Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Carisma Therapeutics, ONWARD, Sidekick, SNIPR Biome and STipe Therapeutics. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), and Middle Peak Medical (acquired by Symetis / Boston Scientific), represented Wellington Partners of the Board of Themis (acquired by MSD), and served as the Spokesperson for the Board of the German PE and VC Association (BVK). Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences. Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC) and F-star (NASDAQ,: FSTX), and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners and McKinsey. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry, and was as post-doctoral researcher at the MRC, Cambridge UK In addition, Regina serves as Chairperson of the Board of one of Europe’s leading start-up incubator INITS in Vienna Austria, and as a Board Member of Copenhagen based BII BioInnovation Institute, and on EIT Health Goldtrack programme's Expert Council.